non-small cell lung cancer
Conditions
Interventions
Case series:Hybrid SBRT-IMRT
Sponsors
Fujian Provincial Tumor Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged = 18 years; 2. ECOG performance status of 0–2; 3. Patients must have histologically or cytologically proven non-small cell lung cancer.Patients must be clinical AJCC stage T1-2, N2-3, M0 (AJCC, 8th ed.) with non-operable disease; nonoperable disease will be determined by thoracic surgeon, radiation oncologist and a medical oncologist, or pulmonologist; 4. Patients with clinical AJCC stage T1-2, N1, M0 (AJCC, 8th edition) who are medically inoperable or refuse surgery are eligible; 5. Patients with tumors invade the chest wall or ipsilateral pulmonary nodules (T3, or T4) are eligible if SBRT is feasible; 6. Patients with clinical AJCC stage T3-4, N2-3, M0 (AJCC, 8th edition) are eligible if the primary tumors are successfully downstaged by induction chemotherapy or targeted therapy; 7. Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study; 8. The patient must provide study-specific informed consent prior to study entry.
Exclusion criteria
Exclusion criteria: 1. Patients with any component of small cell lung carcinoma are excluded; 2. Patients with evidence of a malignant pleural or pericardial effusion are excluded; 3. The treatment plan cannot meet the dose constraints of the organs at risk for Hybrid SBRT-IMRT; 4. Prior invasive malignancy unless disease free for a minimum of 3 years; 5. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. 6. Severe, active co-morbidity such as unstable angina and/or congestive heart failure, transmural myocardial infarction, acute bacterial or fungal infection, Chronic Obstructive Pulmonary Disease, hepatic insufficiency and Acquired Immune Deficiency Syndrome (AIDS); 7. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local Control Rate;Toxicity;Regional Control Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactBuhong Zheng
Fujian Provincial Tumor Hospital
Outcome results
None listed